XML 54 R35.htm IDEA: XBRL DOCUMENT
v3.25.1

Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Textual) - USD ($) |  | 1 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | ---
Oct. 05, 2023 | Dec. 31, 2024 | Dec. 31, 2026 | Dec. 31, 2025 | Dec. 31, 2024 | Dec. 31, 2023 | Nov. 30, 2024 | Jun. 27, 2024 | Dec. 01, 2020
Revenue from Contract with Customer, Excluding Assessed Tax |  |  |  |  | $ 3,495,389 | $ 2,898,806 |  |  |
Alphazyme [Member] |  |  |  |  |  |  |  |  |
Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer |  |  |  |  | 0 |  |  |  |
Proceeds from Sale, Maturity and Collection of Investments |  |  |  |  |  | 1,300,000 |  |  |
Alphazyme [Member] |  |  |  |  |  |  |  |  |
Ownership Percentage |  |  |  |  |  |  |  |  | 1.99%
Research and Development [Member] |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  |  |  |  | 1,605,220 | 2,545,865 |  |  |
Gates Foundation [Member] |  |  |  |  |  |  |  |  |
Accounts Receivable, after Allowance for Credit Loss |  |  |  |  |  |  | $ 3,092,136 |  |
Proceeds From Grant |  | $ 800,000 |  |  |  |  |  |  |
Gates Foundation [Member] | Research and Development [Member] |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  |  |  |  | 0 |  |  |  |
Gates Foundation [Member] | Forecast [Member] |  |  |  |  |  |  |  |  |
Proceeds From Grant |  |  | $ 700,000 | $ 1,500,000 |  |  |  |  |
Proliant Agreement [Member] |  |  |  |  |  |  |  |  |
License and Development, Initial Term (Year) |  |  |  |  |  |  |  | 10 years |
License and Development, Extension Term (Year) |  |  |  |  |  |  |  | 3 years |
Initial Up Front Payment |  |  |  |  |  |  |  | $ 500,000 |
Second Payment Upon Completion Transfer |  |  |  |  |  |  |  | 500,000 |
Final Payment Upon Meeting Certain Productivity Threshold |  |  |  |  |  |  |  | $ 500,000 |
Deferred License Revenue |  |  |  |  | 1,000,000 |  |  |  |
Inzymes Agreement APS [Member] |  |  |  |  |  |  |  |  |
Deferred License Revenue |  |  |  |  | 890,169 |  |  |  |
Non-refundable Upfront Payment, Received | $ 600,000 |  |  |  |  |  |  |  |
Inzymes Agreement APS [Member] | Research and Development [Member] |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  |  |  |  | 25,000 |  |  |  |
A Global Food Ingredient Company [Member] | Research and Development [Member] |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  |  |  |  | 0 | 631,000 |  |  |
Janssen Pharmaceutical Companies [Member] |  |  |  |  |  |  |  |  |
Accounts Receivable, after Allowance for Credit Loss |  | $ 0 |  |  | 0 | 145,000 |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  |  |  |  | $ 0 |  |  |  |
Deferred License Revenue |  |  |  |  |  | 353,000 |  |  |
Janssen Pharmaceutical Companies [Member] | Research and Development [Member] |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  |  |  |  |  | $ 520,000 |  |  |

X
- Definition Represents deferred license revenue. + References No definition available. + Details
Name: | dyai_DeferredLicenseRevenue
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the final payment upon meeting certain productivity thresholds in an agreement. + References No definition available. + Details
Name: | dyai_FinalPaymentUponMeetingCertainProductivityThreshold
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the upfront payment for an agreement. + References No definition available. + Details
Name: | dyai_InitialUpFrontPayment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The duration of the term extension for the research and development agreement. + References No definition available. + Details
Name: | dyai_LicenseAndDevelopmentExtensionTerm
Namespace Prefix: | dyai_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition The initial term length for the research and development agreement. + References No definition available. + Details
Name: | dyai_LicenseAndDevelopmentInitialTerm
Namespace Prefix: | dyai_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents non-refundable upfront payment, received. + References No definition available. + Details
Name: | dyai_NonrefundableUpfrontPaymentReceived
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of ownership. + References No definition available. + Details
Name: | dyai_OwnershipPercentage
Namespace Prefix: | dyai_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of proceeds from grant. + References No definition available. + Details
Name: | dyai_ProceedsFromGrant
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the second payment upon the completion of a transfer in an agreement. + References No definition available. + Details
Name: | dyai_SecondPaymentUponCompletionTransfer
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details
Name: | us-gaap_AccountsReceivableNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details
Name: | us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3 + Details
Name: | us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_AlphazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=dyai_ResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dyai_GatesFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dyai_ProliantAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dyai_InzymesAgreementApsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dyai_AGlobalFoodIngredientCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dyai_JanssenPharmaceuticalCompaniesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |